Quebec-based PENDOPHARM, a division of Pharmascience Inc., today announced Health Canada approval and market availability of IBAVYRTM (ribavirin tablets), the first stand-alone oral ribavirin for the...

Cellceutix announced another important milestone in the development of Brilacidin™, the lead compound in a novel class of antibiotics known as defensin-mimetics.   In the Company’s phase 2b study...

New antimicrobials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by such microorganisms as Staphylococcus aureus, including methicillin-resistant strains (MRSA)...

The number of skin and soft tissue infections (SSTI) has skyrocketed due to the spread of methicillin resistant Staphylococcus aureus (MRSA). But many SSTIs – even those caused by the superbug MRSA –...

PRESS RELEASE The U.S. Food and Drug Administration today approved Dalvance (dalbavancin), a new antibacterial drug used to treat adults with skin infections. Dalvance is intended to treat acute bacterial...

PRESS RELEASE WASHINGTON, DC – May 19, 2014 – A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical...

A New Castle County, Delaware man is the first known infection with New Delhi metallo-beta-lactamase (NDM)–producing carbapenem-resistant Pseudomonas aeruginosa in the United States, according to...

NEWS RELEASE 30 APRIL 2014 | GENEVA – A new report by WHO–its first to look at antimicrobial resistance, including antibiotic resistance, globally–reveals that this serious threat is no longer...

In recent weeks there has been the release of a new product that suffocates head lice and a study by French and British researchers that show the effectiveness of an oral medication to treat head lice...

The World Health Organization (WHO) and the Ugandan Ministry of Health are unveiling a new drug to treat advanced sleeping sickness. The new drug is a combination of eflornithine and nifurtimox have been...